BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that an abstract evaluating Renevia ® in 'run-in' patients with HIV-associated facial lipoatrophy from the Renevia-02 trial will be presented at the 14th annual International Federation for Adipose Therapeutics and Science meeting ( IFATS) taking place from November 17-20, 2016, in San Diego, California. The data will be reported in an oral presentation on Thursday, November 17. The presentation will be given by Ramon Llull, MD, PhD, director of Stem Europe Mallorca Center in Mallorca, Spain, and the principal investigator of the Renevia trial. Dr. Llull will present data from 'run-in' patients in the pivotal trial. The data indicate that Renevia was safely administered with no serious adverse events and 3-D imaging suggests that volumetric improvements were sustained through a one-year follow up. In addition, Dr. Llull will present the mechanistic rationale and pre-clinical data on how Renevia may be able to generate new facial tissue after transplantation. Presentation details: Thursday, November 17 "Stromal Cell-Hydrogel Construct Possibly Generates Clinically Relevant Neo-Tissue In Facial HIV-Lipoatrophy Phase 2 Pivotal Multicenter Clinical Trial: Early Analysis On Testing Patient Sample".Ramon Llull, MD, PhD, Stem Europe Mallorca Center, Mallorca, Spain Additionally, data from the laboratory of Derrick C. Wan, MD, Associate Professor in the Department of Surgery at Stanford University Medical Center, will be presented on pre-clinical data from the transplantation of Renevia into a novel mouse model. Presentation details: Thursday, November 17 "Three Dimensional Ultrasound For The Accurate Imaging And Quantification Of Adipose And Synthetic Tissue Grafts".Charles P. Blackshear MD, MD, Department of Surgery, Stanford University Medical CenterAbout Facial Lipoatrophy Facial wasting or facial lipoatrophy is the loss of subcutaneous fat from the face and is associated with medication for treatment of HIV infection. The longer a person is on HIV medications, the greater the likelihood of developing problems with facial wasting. Signs of lipoatrophy include the loss of subcutaneous fat primarily in the temporal region and cheeks and this tends to produce an emaciated appearance.